A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With Erlotinib as Second- or Third-Line Treatment for Patients With MET-Positive Incurable Stage IIIB/IV Non-Small Cell Lung Cancer

Hoffmann-La Roche8 sites in 1 country530 target enrollmentJanuary 22, 2014

ConditionsNon-Small Cell Lung Cancer

Interventionserlotinib [Tarceva]Placebo Onartuzumab [MetMAb]

Drugserlotinib [Tarceva]Placebo Onartuzumab [MetMAb]

Overview

Phase: Phase 3
Intervention: erlotinib [Tarceva]
Conditions: Non-Small Cell Lung Cancer
Sponsor: Hoffmann-La Roche
Enrollment: 530
Locations: 8
Primary Endpoint: Overall survival (OS)
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This randomized, Phase III, double-blind, placebo-controlled study will evaluate the safety and efficacy of MetMAb (onartuzumab) in combination with Tarceva (erlotinib) compared with treatment with Tarceva alone in patients with incurable Met-positive non-small cell lung cancer (NSCLC). Patients will be randomized in a 2:1 ratio to receive either MetMAb + Tarceva or placebo + Tarceva. Tarceva (150 mg) will be given orally once daily, and MetMAb (15 mg/kg) will be given intravenously every 3 weeks. Treatment will continue until disease progression, unacceptable toxicity, a decision to discontinue, or death occurs. Total study length is expected to be around 36 months.

Registry

clinicaltrials.gov

Start Date

January 22, 2014

End Date

January 6, 2016

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Hoffmann-La Roche

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male or female, 18 years or older.
•Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-
•Histologically confirmed incurable Stage IIIB/IV NSCLC tumor.
•Met-positive status and results of epidermal growth factor receptor (EGFR)-activating mutation testing.
•Available tumor tissue sample or agreement to take such a sample.
•Radiographic evidence of disease. Lesions must be outside a previous radiotherapy field if they are the sole site of disease, unless disease progression has occurred at that site since radiation.
•Prior treatment with at least one platinum-based line of treatment for locally advanced, unresectable/inoperable disease or metastatic disease, and no more than one additional line of chemotherapy treatment, defined as follows:
•Adjuvant/neoadjuvant chemotherapy or chemoradiation counts as a line of therapy if \< 12 months have elapsed between the last dose and the date of recurrence. Combined treatment with chemotherapy and radiation constitutes a single regimen; surgery is not considered a regimen.
•Cytotoxic maintenance therapy that differs from first-line therapy is considered an additional line of therapy. However, changes in treatment due to intolerance or excessive toxicity are not considered an additional regimen.
•The last dose of prior chemotherapy must have been given \>/= 21 days prior to Day 1 (\>/= 14 days for vinorelbine or other vinca alkaloids or gemcitabine).

Exclusion Criteria

•More than 30 days expsoure to an EGFR inhibitor or a known EGFR-toxicity resulting in dose modifications.
•Prior exposure to agents targeting either the HGF or MET pathway, including but not limited to crizotinib, cabozantinib, ficlatuzumab, rilotumumab, and tivantinib.
•Pleural effusion, pericardial fluid, or ascites requiring drainage every other week or more frequently.
•Brain metastases or spinal cord compression that were not definitively treated with surgery and/or radiation or that were previously diagnosed and treated without evidence of clinically stable disease for \>/= 14 days. Patients with treated central nervous system (CNS) metastases who are asymptomatic and on a stable dose of corticosteroid for \>/= 14 days prior to randomization are eligible.
•History of another cancer in the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin cancer, stage I uterine cancer, or other cancers that are curable.
•Life expectancy \< 12 weeks.
•Radiographically visible interstitial lung disease (ILD) or a history of it. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
•Inadequate hematologic, biological, or organ function.
•Significant history of cardiac disease.
•Serious active infection at the time of randomization or other serious underlying medical conditions that would impair the ability of the patient to receive protocol treatment, including positive HIV or active hepatitis B or C infections, significant gastrointestinal abnormalities, uncontrolled diabetes.

Arms & Interventions

erlotinib [Tarceva] + onartuzumab [MetMAb]

Intervention: erlotinib [Tarceva]

erlotinib [Tarceva] + placebo

Intervention: erlotinib [Tarceva]

erlotinib [Tarceva] + placebo

Intervention: Placebo

erlotinib [Tarceva] + onartuzumab [MetMAb]

Intervention: Onartuzumab [MetMAb]

Outcomes

Primary Outcomes

Overall survival (OS)

Time Frame: Up to 36 months

Incidence of adverse events

Time Frame: Up to 33 months

Secondary Outcomes

Progression-free survival (PFS), defined as time from randomization until progression as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death.(Up to 36 months)
Overall response rate (ORR), as measured by RECIST v1.1(Up to 36 months)
Health-related quality of life (HRQOL) as measured by the European Organization for the Research and Treatment of Cancer (EORTC) assessments(Up to 33 months)
Incidence of anti-therapeutic antibodies against MetMAB(Up to 33 months)